Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN124 in Polycythemia Vera
NCT05499013Phase 2Active, not recruiting
- Sponsor
- Silence Therapeutics
- Start
- Jan 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of SLN124 in polycythemia vera (PV) (3 arms), sponsored by Silence Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 239 days, Number of Phlebotomies at 239 days and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
SLN124
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05499013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499013.